Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors.

Cell Rep Med · 2024 · PMC11524974 · PMID 39208799

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

14 , 15 , 16 Conversely, differential expression analysis revealed a highly significant downregulation of SHH pathway components after gemcitabine treatment ( Figure 3 C).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.